Therapeutic modulators of peroxisome proliferator-activated receptors (PPAR): a patent review (2008–present)

Author： Lamers Christina   Schubert-Zsilavecz Manfred   Merk Daniel  

Publisher： Informa Healthcare

ISSN： 1354-3776

Source： Expert Opinion on Therapeutic Patents, Vol.22, Iss.7, 2012-07, pp. : 803-841

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

PPAR Modulators and PPAR Pan Agonists for Metabolic Diseases: The Next Generation of Drugs Targeting Peroxisome Proliferator-Activated Receptors?

By  

Current Topics in Medicinal Chemistry, Vol. 8, Iss. 9, 2008-06 ,pp. : 728-749

Bentham Science Publishers

Access to resources Recommend Favorite

Enantioselective Synthesis of PPAR (Peroxisome Proliferator-Activated Receptors) Agonists and Antagonists

By  

Current Topics in Medicinal Chemistry, Vol. 14, Iss. 10, 2014-05 ,pp. : 1283-1293

Bentham Science Publishers

Access to resources Recommend Favorite

Analysis of patent applications relating to peroxisome proliferator-activated receptor (PPAR) ligands in 2004

By Miyachi Hiroyuki  

Expert Opinion on Therapeutic Patents, Vol. 15, Iss. 11, 2005-11 ,pp. : 1521-1530

Informa Healthcare

Access to resources Recommend Favorite

Peroxisome Proliferator-Activated Receptor (PPAR)&bgr; /&dgr;: A New Potential Therapeutic Target for the Treatment of Metabolic Syndrome

By  

Current Molecular Pharmacology, Vol. 2, Iss. 1, 2009-01 ,pp. : 46-55

Bentham Science Publishers

Access to resources Recommend Favorite

Peroxisome Proliferator-Activated Receptor (PPAR) Gamma Agonists as Therapeutic Agents for Cardiovascular Disorders: Focus on Atherosclerosis

By  

Current Pharmaceutical Design, Vol. 23, Iss. 7, 2017-04 ,pp. : 1119-1124

Bentham Science Publishers

Access to resources Recommend Favorite